Document Detail


Efficacy of omeprazole in lower grades of gastro-oesophageal reflux disease.
MedLine Citation:
PMID:  8047827     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Grade I oesophagitis is usually considered to be a less severe form of gastro-oesophageal reflux disease (GORD). However, with regard to symptom severity, patients without macroscopic mucosal lesions have been shown not to differ from those with more severe oesophagitis. A number of controlled trials on the efficacy of omeprazole in GORD have included patients with lower grades of the disease. The results show that the differences in efficacy between omeprazole and H2-receptor antagonists, which have been established for the treatment of erosive and ulcerative oesophagitis, also extend to patients with grade I oesophagitis (erythema and friability). In these studies, omeprazole provided more rapid symptom resolution and histological improvement than ranitidine. In one double-blind comparative trial, complete endoscopic normalization of the oesophageal mucosa was observed in 90% of patients with grade I oesophagitis within 4 weeks of treatment with omeprazole, 40 mg once daily, compared with 55% of those treated with ranitidine, 150 mg twice daily; at 8 weeks the mucosa in all patients in the omeprazole group had completely healed at endoscopy, while oesophagitis was still present in 21% of the patients receiving ranitidine. A separate 6-month, placebo-controlled maintenance study was performed in patients who had completed a short-term study and who had total relief from the major symptoms of GORD and complete healing of endoscopic oesophagitis. All patients given placebo had an endoscopic recurrence (i.e. endoscopic grade I or more) and this was associated with the return of symptoms in 75% of cases.(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
T Havelund; L S Laursen; K Lauritsen
Related Documents :
21743857 - Multiple facial plaques - a case study.
7887537 - Pyloric channel ulcers: management and three-year follow-up.
11419827 - Pantoprazole therapy in the long-term management of severe acid peptic disease: clinica...
7011357 - Factitious urticaria (dermographism): treatment by cimetidine and chlorpheniramine in a...
24585907 - Staplers versus hand-sewing for pulmonary lobectomy: randomized controlled trial.
19729517 - The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: ...
Publication Detail:
Type:  Comparative Study; Journal Article; Review    
Journal Detail:
Title:  Scandinavian journal of gastroenterology. Supplement     Volume:  201     ISSN:  0085-5928     ISO Abbreviation:  Scand. J. Gastroenterol. Suppl.     Publication Date:  1994  
Date Detail:
Created Date:  1994-09-01     Completed Date:  1994-09-01     Revised Date:  2008-02-13    
Medline Journal Info:
Nlm Unique ID:  0437034     Medline TA:  Scand J Gastroenterol Suppl     Country:  NORWAY    
Other Details:
Languages:  eng     Pagination:  69-73     Citation Subset:  IM    
Affiliation:
Dept. of Medical Gastroenterology, Odense University Hospital, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cimetidine / therapeutic use
Clinical Trials as Topic
Double-Blind Method
Gastroesophageal Reflux / drug therapy*,  physiopathology
Humans
Omeprazole / administration & dosage,  therapeutic use*
Ranitidine / therapeutic use
Chemical
Reg. No./Substance:
51481-61-9/Cimetidine; 66357-35-5/Ranitidine; 73590-58-6/Omeprazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Symptoms and disease severity in gastro-oesophageal reflux disease.
Next Document:  Pathophysiology of Helicobacter pylori infection.